2023
Once-weekly glucagon-like peptide-1 receptor agonists vs dipeptidyl peptidase-4 inhibitors: cardiovascular effects in people with diabetes and cardiovascular disease
Tan X, Liang Y, Rajpura J, Yedigarova L, Noone J, Xie L, Inzucchi S, de Havenon A. Once-weekly glucagon-like peptide-1 receptor agonists vs dipeptidyl peptidase-4 inhibitors: cardiovascular effects in people with diabetes and cardiovascular disease. Cardiovascular Diabetology 2023, 22: 319. PMID: 37985992, PMCID: PMC10662529, DOI: 10.1186/s12933-023-02051-8.Peer-Reviewed Original ResearchConceptsHealth care resource utilizationAtherosclerotic cardiovascular diseaseGLP-1 RAsCause health care resource utilizationPeptide-1 receptor agonistsDipeptidyl peptidase-4 inhibitorsDPP-4i usersPeptidase-4 inhibitorsMyocardial infarctionMedical costsDPP-4iIschemic strokeReceptor agonistCardiovascular diseaseGlucagon-like peptide-1 receptor agonistsWeekly glucagon-like peptide-1 receptor agonistWeekly GLP-1 RAsCause ER visitsCause hospitalization costsCause medical costsNew adult usersClinical cardiovascular outcomesObservational cohort studyType 2 diabetesCause outpatient visits
2020
Blood pressure reduction and outcome after endovascular therapy: a secondary analysis of the BEST study
Anadani M, de Havenon A, Yaghi S, Mehta T, Arora N, Starosciak AK, La Rosa F, Siegler J, Mistry AM, Chitale R, Spiotta AM, Tsivgoulis G, Khatri P, Mistry EA. Blood pressure reduction and outcome after endovascular therapy: a secondary analysis of the BEST study. Journal Of NeuroInterventional Surgery 2020, 13: 698-702. PMID: 32883780, PMCID: PMC8088286, DOI: 10.1136/neurintsurg-2020-016494.Peer-Reviewed Original ResearchConceptsSystolic blood pressure reductionSystolic blood pressureBlood pressure reductionEndovascular therapyPoor functional outcomeSuccessful recanalizationBlood pressurePoor outcomeFunctional outcomeOutcome groupAdmission systolic blood pressureOutcomes of EVTProspective observational cohort studyBaseline systolic blood pressureElevated systolic blood pressurePressure reductionHistory of hypertensionObservational cohort studyPoor outcome groupProspective multicenter cohortGood outcome groupAntihypertensive treatmentRevascularization statusCohort studyMulticenter cohort